These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 4933388)

  • 21. Effect of combined clofibrate-cholestyramine treatment on serum and tissue cholesterol pools and on cholesterol synthesis in hypercholesterolemic swine.
    Kim DN; Lee KT; Reiner JM; Thomas WA
    Exp Mol Pathol; 1975 Aug; 23(1):83-95. PubMed ID: 1157892
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
    Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of primary hyperlipemia].
    Schneider J; Kaffarnik H
    Dtsch Med Wochenschr; 1971 May; 96(19):831-2. PubMed ID: 5574353
    [No Abstract]   [Full Text] [Related]  

  • 24. [The treatment of essential hyperlipidemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of hypercholesterolemia with Secholex. A long-term clinical trial and comparison with cholestyramine.
    Nikkila EA; Miettinen TA; Lanner A
    Atherosclerosis; 1976 Sep; 24(3):407-19. PubMed ID: 971343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia.
    O'Brien RC; Simons LA; Clifton P; Cooper ME; Jennings GL; Jerums G; Nestel PJ; Sullivan D
    Med J Aust; 1990 May; 152(9):480-3. PubMed ID: 2199801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biliary lipid composition during treatment with different hypolipidaemic drugs.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1979 Jun; 9(3):185-90. PubMed ID: 113218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of fenofibrate and clofibrate hypolipidemic effects.
    Daubresse JC
    Acta Clin Belg; 1980; 35(4):227-32. PubMed ID: 7015771
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of parachlorophenoxyisobutyric acid (CPIB acid) and of diet on blood cholesterol and on the beta-alpha lipoprotein ratio in aged subjects].
    Bronzini A; Di Gregorio D; Scotti G
    G Gerontol; 1969 Nov; 17(11):1067-75. PubMed ID: 5397791
    [No Abstract]   [Full Text] [Related]  

  • 30. The chemotherapy of hypercholesterolaemia.
    Heffernan A; Hickey N; Mulcahy R; Fitzgerald O
    Acta Cardiol; 1969; 24(1):47-55. PubMed ID: 5310563
    [No Abstract]   [Full Text] [Related]  

  • 31. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New microporous cholestyramine analog for treatment of hypercholesterolemia.
    De Simone R; Conti F; Lovati MR; Sirtori M; Cocuzza E; Sirtori CR
    J Pharm Sci; 1978 Dec; 67(12):1695-8. PubMed ID: 722483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
    Smit JW; Van Erpecum KJ; Portincasa P; Renooij W; Erkelens DW; Van Berge-Henegouwen GP
    Gut; 1995 Nov; 37(5):654-9. PubMed ID: 8549941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clofibrate banned - what now? (author's transl)].
    Schwartzkopff W
    MMW Munch Med Wochenschr; 1979 Apr; 121(15):529-33. PubMed ID: 108569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, biochemical and pathological studies of long term "clofibrate" therapy.
    el-Mehairy MM; Attia O; Nabih AE; Nassar I; Ibrahim WN
    J Trop Med Hyg; 1970 Jul; 73(7):177-81. PubMed ID: 5470220
    [No Abstract]   [Full Text] [Related]  

  • 39. Preventing myocardial infarction: cholestyramine (Questran) and other hypolipidemics.
    Pepper GA
    Nurse Pract; 1986 Mar; 11(3):84, 86, 88. PubMed ID: 3951771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy of Questran Light, a new formulation of cholestyramine powder, to regular Questran in maintaining lowered plasma cholesterol levels.
    Insull W; Marquis NR; Tsianco MC
    Am J Cardiol; 1991 Mar; 67(6):501-5. PubMed ID: 1998281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.